BTX306
/ BioTheryX
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
July 11, 2020
"The novel protein homeostatic modulator BTX306 is active in #myeloma and overcomes bortezomib and lenalidomide resis… https://t.co/mtb4YmDZAA"
(@Myeloma_Doc)
Hematological Malignancies • Multiple Myeloma • Oncology
1 to 1
Of
1
Go to page
1